Market-leading nerve repair device secures inclusion on Prostheses List

MedTech News: The Australian addressable market for nerve repair and reconstruction is significant, with 11,780 surgical repairs of peripheral nerves completed in public and private hospitals in the 2019/20 financial year.

Regenerative device company, Orthocell, has secured the inclusion of Remplir on the Prostheses List (PL) which enables surgeons to receive reimbursement from private insurers for its use in peripheral nerve repair procedures reducing costs to the patient.

Orthocell Managing Director, Paul Anderson, said “Inclusion of Remplir on the Prostheses List is the
culmination of translational research and a regulatory program to bring this product to the Australian market. I am delighted that patients now have access to a premium nerve repair device that has been designed, manufactured and now reimbursed in Australia.”

Australia first to secure funding of digital health platform for neurology patients

The company believes Remplir will become the market-leading nerve repair device, with uptake driven by the surgeon’s preference for high quality, easy to use devices that reduce the need for damaging sutures and facilitates better patient outcomes.

The PL inclusion follows Australian market approvals for Remplir medical device in March 2022 and the appointment of Device Technologies as the exclusive distributor of Remplir across Australia and New Zealand in September 2022. Device Technologies will market and distribute Remplir, undertaking targeted promotion activities, initiating sales and expanding the network of referring plastic and orthopaedic surgeons.

Orthocell have been actively working with the internal sales and marketing team at Device Technologies preparing for Australian market entry, leading in-person product training sessions and participating in marketing workshops.

Remplir is manufactured by Orthocell at its quality-controlled facility in WA, using the company’s proprietary SMRT manufacturing technology developed in conjunction with Professor Minghao Zheng and the University of Western Australia.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.